<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cent Nerv Syst Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Cent Nerv Syst Dis</journal-id><journal-title-group><journal-title>Journal of Central Nervous System Disease</journal-title></journal-title-group><issn pub-type="epub">1179-5735</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3891626</article-id><article-id pub-id-type="doi">10.4137/JCNSD.S12938</article-id><article-id pub-id-type="publisher-id">jcnsd-6-2014-001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Aromatic Amino Acid Decarboxylase Deficiency Not Responding to Pyridoxine and Bromocriptine Therapy: Case Report and Review of Response to Treatment </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alfadhel</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="af1-jcnsd-6-2014-001">1</xref><xref ref-type="corresp" rid="c1-jcnsd-6-2014-001"/></contrib><contrib contrib-type="author"><name><surname>Kattan</surname><given-names>Rana</given-names></name><xref ref-type="aff" rid="af2-jcnsd-6-2014-001">2</xref></contrib></contrib-group><aff id="af1-jcnsd-6-2014-001"><label>1</label>Division of Genetics, Department of Pediatrics, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia.</aff><aff id="af2-jcnsd-6-2014-001"><label>2</label>Division of General Pediatrics, Department of Pediatrics, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia.</aff><author-notes><corresp id="c1-jcnsd-6-2014-001">CORRESPONDENCE: <email>dralfadhel@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>07</day><month>1</month><year>2014</year></pub-date><volume>6</volume><fpage>1</fpage><lpage>5</lpage><history><date date-type="received"><day>04</day><month>8</month><year>2013</year></date><date date-type="rev-recd"><day>03</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>11</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>© 2014 the author(s), publisher and licensee Libertas Academica Ltd.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Aromatic L-amino acid decarboxylase (AADC) deficiency (MIM #608643) is an autosomal recessive inborn error of monoamines. </plain></SENT>
<SENT sid="2" pm="."><plain>It is caused by a mutation in the DDC gene that leads to a deficiency in the AADC enzyme. </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical features of this condition include a combination of dopamine, noradrenaline, and serotonin deficiencies, and a patient may present with hypotonia, oculogyric crises, sweating, hypersalivation, autonomic dysfunction, and progressive encephalopathy with severe developmental delay. </plain></SENT>
<SENT sid="4" pm="."><plain>We report the case of an 8-month-old boy who presented with the abovementioned symptoms and who was diagnosed with AADC deficiency based on clinical, biochemical, and molecular investigations. </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with bromocriptine and pyridoxine showed no improvement. </plain></SENT>
<SENT sid="6" pm="."><plain>These data support the findings observed among previously reported cohorts that showed poor response of this disease to current regimens. </plain></SENT>
<SENT sid="7" pm="."><plain>Alternative therapies are needed to ameliorate the clinical complications associated with this disorder. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>aromatic L-amino acid decarboxylase deficiency</kwd><kwd>AADC</kwd><kwd>amino acid decarboxylase</kwd><kwd>neurotransmitter</kwd><kwd>dopamine</kwd><kwd>noradrenaline</kwd><kwd>serotonin</kwd><kwd>oculogyric crises</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="8" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="9" pm="."><plain>Aromatic L-amino acid decarboxylase (AADC) deficiency (Online Mendelian Inheritance in Man (OMIM® #608643) is an autosomal recessive neurotransmitter disorder.1–3 It is caused by a deficiency in AADC due to a mutation in the AADC gene (DDC) on chromosome 12p12.3-p12.3,4 This leads to deficiencies in combined monoamines, catecholamines, and serotonin. </plain></SENT>
<SENT sid="10" pm="."><plain>It is characterized clinically by global developmental delay, truncal hypotonia, oculogyric crises, dystonia, sweating, severe progressive epileptic encephalopathy, and other signs of catecholamine and serotonin deficiencies.2–5 Diagnosis relies on the presence of a characteristic cerebrospinal fluid (CSF) profile (low homovanillic acid, 5-hydroxyindoleacidicacid, and 3-methoxy-4-hydroxyphenolglycole, as well as elevated 3-O-methyl-L-dopa, L-dopa, and 5-hydroxytryptophan), the absence of plasma AADC activity, or elevated urinary vanillactic acid, and confirmation of the sequencing of the DOPA decarboxylase (DDC) gene.2,3,6 To date, there is no cure for AADC deficiency, and there are conflicting data in the literature regarding the best treatment options.7 However, the first-line medications appear to be dopamine agonists, such as bromocriptine combined with pyridoxine.3,4 We report the case of an 8-month-old boy diagnosed with an AADC deficiency who did not respond to bromocriptine and pyridoxine treatment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CASE"><sec><title><text><SENT sid="11" pm="."><plain>Case Report </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>An 8-month-old full-term baby (with normal vaginal delivery) born to Saudi first-cousin parents who met appropriate growth parameters and did not have a significant antenatal history. </plain></SENT>
<SENT sid="13" pm="."><plain>He was discharged at the second day of life with no complications. </plain></SENT>
<SENT sid="14" pm="."><plain>The child presented to King Abdulaziz Medical City at 4.5 months of age when he developed a fever and flu-like symptoms, requiring admission to the Pediatric Intensive care Unit for 5 days. </plain></SENT>
<SENT sid="15" pm="."><plain>On reviewing his clinical history, the parents noticed that he was floppy a few days after birth. </plain></SENT>
<SENT sid="16" pm="."><plain>In addition, they noticed abnormal posturing of his right lower limbs with eye conversion that last for few minutes, but which recurred frequently at 2 months of age. </plain></SENT>
<SENT sid="17" pm="."><plain>Furthermore, he demonstrated excessive sweating and difficulties with feeding. </plain></SENT>
<SENT sid="18" pm="."><plain>His developmental history showed a global developmental delay with poor head control; there was no cooing, no social smile, he did not roll over, and he did not sit. </plain></SENT>
<SENT sid="19" pm="."><plain>His developmental age was equal to 1 month. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>On examination, the growth parameters showed the following: length, 82 cm (50th percentile); weight, 11.07 kg (2nd percentile); and head circumference, 47 cm (50th percentile) with no dysmorphic features or neurocutaneous stigmata. </plain></SENT>
<SENT sid="21" pm="."><plain>Neurological examination showed: bilateral positive red reflex; not fixing or following; axial hypotonia with peripheral hypertonia; dystonic posture; and hyperreflexia of all limbs. </plain></SENT>
<SENT sid="22" pm="."><plain>Other systemic examinations demonstrated no significant abnormalities. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Additional diagnostic investigations were unrevealing. </plain></SENT>
<SENT sid="24" pm="."><plain>Continuous electroencephalogram (EEG) monitoring for 2 days was normal, and it was concluded that these attacks were consistent with occulogyris crises. </plain></SENT>
<SENT sid="25" pm="."><plain>An echocardiogram was normal. </plain></SENT>
<SENT sid="26" pm="."><plain>Brain computed tomography (CT) was normal. </plain></SENT>
<SENT sid="27" pm="."><plain>Brain and spine magnetic resonance imaging (MRI) showed no intracranial abnormality. </plain></SENT>
<SENT sid="28" pm="."><plain>Auditory brainstem response showed a central defect in the right auditory pathway. </plain></SENT>
<SENT sid="29" pm="."><plain>The ophthalmologic evaluation was normal. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>All the following investigations were also unremarkable: complete blood count, liver enzymes, serum electrolytes and renal function. </plain></SENT>
<SENT sid="31" pm="."><plain>Biochemical investigations included acylcarnitine profile, plasma aminoacids were unremarkable. </plain></SENT>
<SENT sid="32" pm="."><plain>Urine organic acids showed moderately elevated homovanillic acid and slight elevation of methylglutaric and methylglutaconic acids. </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>A neurotransmitter metabolite cerebrospinal fluid (CSF) panel showed reduced concentrations of homovanillic acid 60 nmol/L (403–919 nmol/L) and 5-OH-indolacetic acid 93 nmol/L (170–412 nmol/L), as well as their ratio of 0.6 (1.8–3), and a clearly increased concentration of 3-ortho methyl dopa of 2,076 nmol/L (0–50 nmol/L). </plain></SENT>
<SENT sid="34" pm="."><plain>The plasma levels of amine neurotransmitter metabolites showed the following: vanillymandelicacid (3.9; 12–73 nmol/L), 3-methoxy-4-hydroxy-phenylglycol (2.4; 9–37 nmol/L) and homovanillic acid (19.3; 43–131 nmol/L) were strongly decreased; while 5-hydroxyindolacetic acid was borderline low (33.1; 21–183 nmol/L). </plain></SENT>
<SENT sid="35" pm="."><plain>Vanillactic acid (478 nmol/L), which is the metabolite of a dopamine precursor, was strongly increased; this metabolite pattern is fully characteristic of an AADC deficiency. </plain></SENT>
<SENT sid="36" pm="."><plain>The plasma AADC enzyme activity was 4 pmol/mlMin (47–119 pmol/mlMin) which is clearly reduced. </plain></SENT>
<SENT sid="37" pm="."><plain>Sequence analysis of the DDC gene identified a homozygous missense mutation c.1234C&gt;T (p. </plain></SENT>
<SENT sid="38" pm="."><plain>R412W). </plain></SENT>
<SENT sid="39" pm="."><plain>The parents were tested and found to be carriers for this mutation. </plain></SENT>
<SENT sid="40" pm="."><plain>After the diagnosis was confirmed, the patient was started on pyridoxine at 100 mg orally, every 12 (q12) hours, and bromocriptine at 10 mg orally q12 hours. </plain></SENT>
<SENT sid="41" pm="."><plain>However, the proband continued to present with agitation and insomnia with no improvement in the duration or frequency of the occulogyris crises. </plain></SENT>
<SENT sid="42" pm="."><plain>Two months later, the medications were stopped, as the patient did not appear to respond to treatment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion"><title><text><SENT sid="43" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>AADC deficiency was first described by Hyland and Clayton in 1990, when they reported on male monozygotic twins who presented at the age of 2 months with severe hypotonia and oculogyric crises.8 Subsequently, AADC deficiency has been reported in almost 80 patients worldwide.1,3,4 The most consistent features associated with this deficiency are those of combined dopamine and noradrenaline deficiency. </plain></SENT>
<SENT sid="45" pm="."><plain>The signs of dopamine deficiency include hypokinesia, rigidity, dystonia (with or without diurnal variations), distal chorea, and oculogyric crises. </plain></SENT>
<SENT sid="46" pm="."><plain>The clinical features of noradrenaline insufficiency include ptosis, miosis, profuse oropharyngeal secretions, postural hypotension, autonomic dysfunction, and temperature instability. </plain></SENT>
<SENT sid="47" pm="."><plain>Similarly, symptoms of serotonin deficiency include sleep disorders, memory and learning disabilities, and behavioral disturbances.9 Hypotonia and oculogyric crises are the most common clinical signs noted across all reported patients.3 The patient presented in this report showed a mixture of these clinical features. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Treatment of AADC deficiency is supportive. </plain></SENT>
<SENT sid="49" pm="."><plain>The most common first-line treatments are bromocriptine and pyridoxine with dosages ranging between 40 mg/day and 1,800 mg/day (4.0–81 mg/kg/day) and 1.0–45.5 mg/day (0.013–4.0 mg/kg/day), respectively. </plain></SENT>
<SENT sid="50" pm="."><plain>Bromocriptine is a dopamine receptor agonist with high affinity for D2-like receptors, 4,10 and has been prescribed to correct motor deficit like hypokinesia, axial hypotonia, limb hypertonia, dystonia and choreoathetosis. </plain></SENT>
<SENT sid="51" pm="."><plain>However, its effect has varied anmong individuals. 4 Pyridoxine or vitamin B6 is also given to patients to boost residual AADC activity with a cofactor excess.10 Other medications used in the management of affected children are monoamine oxidase inhibitors such as selegiline, pergolide, tranylcypromine, trihexyphenidyl, L-dopa, and folinic acid.3,4 Most of the reported patients, as well as current case, showed no response to these therapies (Table 1). </plain></SENT>
<SENT sid="52" pm="."><plain>However, Brun et al.3 (2010) presented 15 patients who improved on a combined therapy with pyridoxine, dopamine agonists, and monoamine oxidase B inhibitors. </plain></SENT>
</text></p><p><text><SENT sid="53" pm="."><plain>Gene therapy is a promising experimental approach to AADC deficiency treatment of AADC deficiency, where the DCC gene may be transferred directly into patients’ cells to stabilize the expression of the AADC protein.10 The feasibility of gene therapy for AADC deficiency is underscored by a recent report of functional motor improvement in four children with AADC deficiency. </plain></SENT>
<SENT sid="54" pm="."><plain>Here, Hwu et al. applied the adeno-associated virus type 2 vector to deliver the DCC gene to the putamen area, without complications.11 </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec><title><text><SENT sid="55" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>We alert clinicians to consider AADC deficiency in any infant with hypotonia and oculogyric crises. </plain></SENT>
<SENT sid="57" pm="."><plain>We note that despite the poor clinical response to current medications, gene therapy shows promise as a treatment for this disorder. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="58" pm="."><plain>We are grateful to the patient and his family reported in this article for their genuine support. </plain></SENT>
<SENT sid="59" pm="."><plain>We also thank Dr. Alexander Rotenberg for editing the manuscript. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn id="fn1-jcnsd-6-2014-001"><p><text><SENT sid="60" pm="."><plain>ACADEMIC EDITOR: Alexander Rotenberg, Editor in Chief </plain></SENT>
</text></p></fn><fn id="fn2-jcnsd-6-2014-001"><p><text><SENT sid="61" pm="."><plain>COMPETING INTERESTS: Author(s) disclose no potential conflicts of interest. </plain></SENT>
</text></p></fn><fn id="fn3-jcnsd-6-2014-001"><p><text><SENT sid="62" pm="."><plain>Author Contributions </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>Wrote the first draft of the manuscript: MAF, RK. </plain></SENT>
<SENT sid="64" pm="."><plain>Contributed to the writing of the manuscript: MAF, RK. </plain></SENT>
<SENT sid="65" pm="."><plain>Agree with manuscript results and conclusions: MAF, RK. </plain></SENT>
<SENT sid="66" pm="."><plain>Jointly developed the structure and arguments for the paper: MAF, RK. </plain></SENT>
<SENT sid="67" pm="."><plain>Made critical revisions and approved final version: MAF. </plain></SENT>
<SENT sid="68" pm="."><plain>All authors reviewed and approved of the final manuscript. </plain></SENT>
</text></p></fn><fn id="fn4-jcnsd-6-2014-001"><p><text><SENT sid="69" pm="."><plain>DISCLOSURES AND ETHICS </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain>As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. </plain></SENT>
<SENT sid="71" pm="."><plain>This article was subject to blind, independent, expert peer review. </plain></SENT>
<SENT sid="72" pm="."><plain>The reviewers reported no competing interests. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn id="fn5-jcnsd-6-2014-001"><p><text4fund><text><SENT sid="73" pm="."><plain>FUNDING: Author(s) disclose no funding sources. </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="b1-jcnsd-6-2014-001"><text><SENT sid="74" pm="."><plain>1MallerAHylandKMilstienSBiaggioniIButlerIJAromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second familyJ Child Neurol91997126349549309516 </plain></SENT>
</text></ref><ref id="b2-jcnsd-6-2014-001"><text><SENT sid="75" pm="."><plain>2HylandKSurteesRARodeckCClaytonPTAromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesisNeurology1019924210198081357595 </plain></SENT>
</text></ref><ref id="b3-jcnsd-6-2014-001"><text><SENT sid="76" pm="."><plain>3BrunLNguLHKengWTClinical and biochemical features of aromatic L-amino acid decarboxylase deficiencyNeurologyJuly 62010751647120505134 </plain></SENT>
</text></ref><ref id="b4-jcnsd-6-2014-001"><text><SENT sid="77" pm="."><plain>4PonsRFordBChiribogaCAAromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosisNeurologyApril 13200462710586515079002 </plain></SENT>
</text></ref><ref id="b5-jcnsd-6-2014-001"><text><SENT sid="78" pm="."><plain>5KorenkeGCChristenHJHylandKHunnemanDHHanefeldFAromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crisesEur J Paediatr Neurol199712–3677110728198 </plain></SENT>
</text></ref><ref id="b6-jcnsd-6-2014-001"><text><SENT sid="79" pm="."><plain>6HylandKClaytonPTAromatic L-amino acid decarboxylase deficiency: diagnostic methodologyClin Chem12199238122405101281049 </plain></SENT>
</text></ref><ref id="b7-jcnsd-6-2014-001"><text><SENT sid="80" pm="."><plain>7ManegoldCHoffmannGFDegenIAromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-upJ Inherit Metab Dis620093233718019172410 </plain></SENT>
</text></ref><ref id="b8-jcnsd-6-2014-001"><text><SENT sid="81" pm="."><plain>8HylandKClaytonPTAromatic amino acid decarboxylase deficiency in twinsJ Inherit Metab Dis199013330141700191 </plain></SENT>
</text></ref><ref id="b9-jcnsd-6-2014-001"><text><SENT sid="82" pm="."><plain>9Grattan-SmithPJWeversRASteenbergen-SpanjersGCFungVSEarlJWilckenBTyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancyMov Disord32002172354911921123 </plain></SENT>
</text></ref><ref id="b10-jcnsd-6-2014-001"><text><SENT sid="83" pm="."><plain>10AllenGFLandJMHealesSJA new perspective on the treatment of aromatic L-amino acid decarboxylase deficiencyMol Genet Metab5200997161419231266 </plain></SENT>
</text></ref><ref id="b11-jcnsd-6-2014-001"><text><SENT sid="84" pm="."><plain>11HwuWLMuramatsuSTsengSHGene therapy for aromatic L-amino acid decarboxylase deficiencySci Transl MedMay 1620124134134ra161 </plain></SENT>
</text></ref><ref id="b12-jcnsd-6-2014-001"><text><SENT sid="85" pm="."><plain>12AbelingNGvan GennipAHBarthPGvan CruchtenAWestraMWijburgFAAromatic L-amino acid decarboxylase deficiency: a new case with a mild clinical presentation and unexpected laboratory findingsJ Inherit Metab Dis6199821324029686366 </plain></SENT>
</text></ref><ref id="b13-jcnsd-6-2014-001"><text><SENT sid="86" pm="."><plain>13SwobodaKJHylandKGoldsteinDSClinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiencyNeurologyOctober 12199953612051110522874 </plain></SENT>
</text></ref><ref id="b14-jcnsd-6-2014-001"><text><SENT sid="87" pm="."><plain>14FiumaraABrautigamCHylandKAromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. </plain></SENT>
<SENT sid="88" pm="."><plain>Clinical and laboratory findings in response to different therapiesNeuropediatrics82002334203812368991 </plain></SENT>
</text></ref><ref id="b15-jcnsd-6-2014-001"><text><SENT sid="89" pm="."><plain>15ChangYTSharmaRMarshJLLevodopa-responsive aromatic L-amino acid decarboxylase deficiencyAnn Neurol32004553435814991824 </plain></SENT>
</text></ref><ref id="b16-jcnsd-6-2014-001"><text><SENT sid="90" pm="."><plain>16TaySKPohKSHylandKUnusually mild phenotype of AADC deficiency in 2 siblingsMol Genet Metab82007914374817533144 </plain></SENT>
</text></ref><ref id="b17-jcnsd-6-2014-001"><text><SENT sid="91" pm="."><plain>17ItoSNakayamaTIdeSAromatic L-amino acid decarboxylase deficiency associated with epilepsy mimicking non-epileptic involuntary movementsDev Med Child Neurol1120085011876818754761 </plain></SENT>
</text></ref><ref id="b18-jcnsd-6-2014-001"><text><SENT sid="92" pm="."><plain>18LeeHFTsaiCRChiCSChangTMLeeHJAromatic L-amino acid decarboxylase deficiency in TaiwanEur J Paediatr Neurol320091321354018567514 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="TABLE"><table-wrap id="t1-jcnsd-6-2014-001" position="float"><label>Table 1</label><caption><p><text><SENT sid="93" pm="."><plain>Summary of published treatments and clinical responses in AADC deficiency treatment. </plain></SENT>
</text></p></caption><table frame="box" rules="rows"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>ARTICLE, YEAR </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>PATIENT NO. </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>M:F </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>RESPONSE TO PYRIDOXINE </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>RESPONSE TO BROMOCRIPTINE </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>ADDITIONAL TREATMENTS </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>RESPONSE TO ADDITIONAL TREATMENTS </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>Hyland et al., 19922 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>M </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>No clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>Slight improvement in oculogyric crises </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>Tranylcypromine Dexamphetamine Imipramine </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>Tranylcypromine: Improved spontaneous movement and also improved muscle tone Dexamphetamine and Imipramine had no clinical response </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>Maller et al., 19971 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>M </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>No clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Partial improvement in muscle tone and head control </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>Tranylcypromine </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>Improvement in muscle tone, spontaneous movement and head control </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>Korenke et al., 19975 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>F </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>Decrease occulogyris crises and improvement in muscle tone </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>Improvement in hypokinesia and hypotonia </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>Levodopa Selegiline </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>Levodopa: decreased extrapyramidal movementSelegiline: temporarily suppressed occulogyris crises, improve muscle tone and bowel function </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>Abeling et al., 199812 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>F </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>Swoboda et al., 199913 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>1:1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>No clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>Decreased the frequency of oculogyric episodes and rigidity </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>L-dopa 5-hydroxytryptophan (5-HTP) Pergolide Tranylcypromine Trihexyphenidyl Buspirone Oxymetazoline hydrochloride Pseudoephedrine hydrochloride Sertraline hydrochloride Midodrine hydrochloride </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>L-dopa: No clinical response5-HTTP: induced l ethargy and worsened axial hypotoniaPergolide: complete resolution of dystonic spells and oculogyric crisesTranylcypromine: improved coordination and spontaneous movement in one patientTrihexyphenidyl: modestly improved tone, limb rigidity, and excessive sweatingBuspirone: reduced limb rigidity and irritability initially, then, led to tardive dyskinesiaOthers: no significant clinical response </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>Fiumara et al., 200214 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>M </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>Partial clinical improvement initially then deteriorate over time </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>Partial clinical improvement initially then deteriorated over time </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>Selegiline L-dopa 5-HTTP Cabergoline </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>Selegiline, L-dopa and 5-HTTP: Slight clinical improvement initially then deteriorate over timeCabergoline: no clinical response </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>Chang et al., 200415 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>2:1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>NP </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>NP </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Levodopa/carbidopa </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>Marked clinical improvement initially but it deteriorated over time </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>Pons et al., 20044 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>3:3 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>3/6 no clinical response, rest are favorable </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>3/6 slight improvement </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>Tranylcypromine Melatonine Pergolide </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>Tranylcypromine and pergolide: 3/6 favorable and rest no clinical responseMelatonin: improvement in sleep pattern </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>Tay et al., 200716 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>F </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Partial clinical improvement </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>Slight clinical improvement </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>Selegiline </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>Improved muscle strength </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>Ito et al., 200817 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>M </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>Partial improvement in vocalization and voluntary movement </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>Partial improvement in vocalization and voluntary movement </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>Valproic acid clobazam </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>Seizure reduction </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>Manegold et al., 20097 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>6:3 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>4/9 with slight improvement </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>2/9 with slight improvement, other, deteriorated after discontinuation of therapy </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>Selegiline, tranylcypromine L-dopa Pergolide </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>Selegiline: used in 3/9 One patient improved temporarily, others deterioratedTranylcypromine: used in 2/9, one deteriorate and one improvedL-dopa: 6/9, three improved and three showed no clinical responsePergolide: 1/9, no clinical response </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>Lee et al., 200918 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>4:4 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>No clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>No clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>Moclobemide Akineton </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>Moclobemide: 2/9, mild improvement in the duration of oculogyric crises and irritabilityAkineton: 3/9, no response </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>Brun et al., 20103 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>78 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>41:31 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>15/55 good clinical response, rest are no clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>15/38 good clinical response, rest are no clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>Selegiline L-dopa Pergolide Tranylcypromide Trihexyphenidyl </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>Selegiline: 19/78L-dopa: 10/78Pergolide : 12/78Tranylcypromide: 22/78Trihexyphenidyl: 15/78All had no clinical response </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>Hwu et al., 201211 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>1:3 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>Gene therapy </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>Weight gain and improved motor function </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>Alfadhel and Kattan, 2013 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>M </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>No clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>No clinical response </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>NP </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>NP </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-jcnsd-6-2014-001"><p><bold>Note:</bold> *given in combination with other drugs.</p></fn><fn id="tfn2-jcnsd-6-2014-001"><p><bold>Abbreviations:</bold> M, male; F, female; NA, not available; NP, not prescribed.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
